Sökning: onr:"swepub:oai:DiVA.org:uu-424548" > Pharmacodynamics, p...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05523naa a2200589 4500 | |
001 | oai:DiVA.org:uu-424548 | |
003 | SwePub | |
008 | 201111s2020 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4245482 URI |
024 | 7 | a https://doi.org/10.1093/eurheartj/ehz8072 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Storey, Robert F.u Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England.4 aut |
245 | 1 0 | a Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes |
264 | c 2019-11-14 | |
264 | 1 | b Oxford University Press (OUP),c 2020 |
338 | a electronic2 rdacarrier | |
520 | a Aims To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y(12) receptor antagonist for subcutaneous administration, in patients with chronic coronary syndromes (CCS). Methods and results In this double-blind, randomized study of 345 patients with CCS on background oral antiplatelet therapy, subcutaneous selatogrel (8 mg, n = 114; or 16 mg, n = 115) was compared with placebo (n = 116) (ClinicalTrials.gov: NCT03384966). Platelet aggregation was assessed over 24 h (VerifyNow assay) and 8 h (light transmittance aggregometry; LTA). Pharmacodynamic responders were defined as patients having P2Y(12) reaction units (PRU) <100 at 30 min post-dose and lasting >= 3 h. At 30 min post-dose, 89% of patients were responders to selatogrel 8 mg, 90% to selatogrel 16 mg, and 16% to placebo (P < 0.0001). PRU values (mean standard deviation) were 10 +/- 25 (8 mg), 4 +/- 10 (16 mg), and 163 +/- 73 (placebo) at 15 min and remained <100 up to 8 h for both doses, returning to pre-dose or near pre-dose levels by 24 h post-dose. LTA data showed similarly rapid and potent inhibition of platelet aggregation. Selatogrel plasma concentrations peaked similar to 30 min post-dose. Selatogrel was safe and well-tolerated with transient dyspnoea occurring overall in 7% (16/229) of patients (95% confidence interval: 4-11%). Conclusions Selatogrel was rapidly absorbed following subcutaneous administration in CCS patients, providing prompt, potent, and consistent platelet P2Y(12) inhibition sustained for >= 8 h and reversible within 24 h. Further studies of subcutaneous selatogrel are warranted in clinical scenarios where rapid platelet inhibition is desirable. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
653 | a Selatogrel | |
653 | a Platelet aggregation | |
653 | a Coronary artery disease | |
653 | a P2Y(12) receptor antagonist | |
653 | a Pharmacodynamics | |
653 | a Pharmacokinetics | |
700 | 1 | a Gurbel, Paul A.u Inova Heart & Vasc Inst, Falls Church, VA USA.4 aut |
700 | 1 | a ten Berg, Jurrienu St Antonius Hosp, Dept Cardiol, Nieuwegein, Netherlands.4 aut |
700 | 1 | a Bernaud, Corineu Idorsia Pharmaceut Ltd, Allschwil, Switzerland.4 aut |
700 | 1 | a Dangas, George D.u Mt Sinai Hosp, Div Cardiol, New York, NY USA.4 aut |
700 | 1 | a Frenoux, Jean-Marieu Idorsia Pharmaceut Ltd, Allschwil, Switzerland.4 aut |
700 | 1 | a Gorog, Diana A.u Univ Hertfordshire, Hatfield, Herts, England.;Imperial Coll, Natl Heart & Lung Inst, London, England.4 aut |
700 | 1 | a Hmissi, Abdelu Idorsia Pharmaceut Ltd, Allschwil, Switzerland.4 aut |
700 | 1 | a Kunadian, Vijayu Newcastle Univ, Fac Med Sci, Newcastle Upon Tyne, Tyne & Wear, England.;Newcastle Tyne Hosp NHS Fdn Trust, Freeman Hosp, Cardiothorac Ctr, Newcastle Upon Tyne, Tyne & Wear, England.4 aut |
700 | 1 | a James, Stefan,d 1964-u Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)stjam367 |
700 | 1 | a Tanguay, Jean-Francoisu Univ Montreal, Inst Cardiol Montreal, Dept Med, Montreal, PQ, Canada.4 aut |
700 | 1 | a Tran, Henryu Inova Heart & Vasc Inst, Falls Church, VA USA.4 aut |
700 | 1 | a Trenk, Dietmaru Univ Heart Ctr Freiburg Bad Krozingen, Dept Cardiol & Angiol 2, Bad Krozingen, Germany.4 aut |
700 | 1 | a Ufer, Mikeu Idorsia Pharmaceut Ltd, Allschwil, Switzerland.4 aut |
700 | 1 | a Van der Harst, Pimu Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands.4 aut |
700 | 1 | a Van't Hof, Arnoud W. J.u Maastricht Univ Med Ctr MUMC, Dept Cardiol, Maastricht, Netherlands.;Zuyderland Med Ctr ZMC, Dept Cardiol, Heerlen, Netherlands.;Isala Hosp, Dept Cardiol, Zwolle, Netherlands.4 aut |
700 | 1 | a Angiolillo, Dominick J.u Univ Florida, Div Cardiol, Coll Med, Jacksonville, FL USA.4 aut |
710 | 2 | a Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England.b Inova Heart & Vasc Inst, Falls Church, VA USA.4 org |
773 | 0 | t European Heart Journald : Oxford University Press (OUP)g 41:33, s. 3132-3140q 41:33<3132-3140x 0195-668Xx 1522-9645 |
856 | 4 | u https://doi.org/10.1093/eurheartj/ehz807y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1500068/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u https://doi.org/10.1093/eurheartj/ehz807 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-424548 |
856 | 4 8 | u https://doi.org/10.1093/eurheartj/ehz807 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.